BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-9 out of 9 found
  Current Search:  xifaxan: 9     

HTML
100%
Summer Street Initiates Coverage of Salix Pharmaceuticals (SLXP) with a Buy
Summer Street initiates coverage of Salix Pharmaceuticals (NASDAQ: SLXP) with a Buy rating.

Price target of $38.

Soleil analyst says, "While shares have significantly appreciated in recent months, we see continued strength ahead.

Xifaxan label...

Street Insider:  Feb 2 2010 6:35PM
Matching: xifaxan
Find similar documents
HTML
100%
Analyst expects FDA to approve Salix drug to treat neurological damage from liver failure
NEW YORK An Oppenheimer analyst said Tuesday that Salix Pharmaceuticals Ltd.

will win new marketing approval for its drug Xifaxan, driving up sales and boosting the company's profit and sales for the year.

John Newman said he thinks the Food and Drug...

DCExaminer.com:  Jan 26 2010 7:23PM
Matching: xifaxan
Find similar documents
HTML
100%
Actionable Call Alert : Salix Pharmaceuticals (NASDAQ:SLXP): Top Pick For 2010 - Piper
Piper Jaffray is out with a major call on Salix Pharmaceuticals (NASDAQ:SLXP) this morning calling the stock their Top Small Cap Pick for 2010 and raising target to $58 (prev.

$29).

The firm believes that Street estimates (including their own) have been...

I Stock Analyst:  Jan 10 2010 10:49AM
Matching: xifaxan
Find similar documents
HTML
100%
Piper Jaffray Names Salix Pharmaceuticals (SLXP) as Top Small Cap Pick for 2010
Piper Jaffray maintains an Overweight rating on Salix Pharmaceuticals (Nasdaq: SLXP), raises price target from $29 to $58.

Piper analyst says, "We are highlighting Salix as our top small-cap specialty pharma pick in 2010.

We believe that Street estimates ...

Street Insider:  Jan 5 2010 12:11PM
Matching: xifaxan
Find similar documents
HTML
100%
UPDATE 1-At least two brokerages up Salix Pharma price target
Jan 5 (Reuters) - Piper Jaffray and Roth Capital raised their price targets on Salix Pharmaceuticals Inc, citing higher price potential for the company's key drug Xifaxan.

While Roth Capital raised its target to $30 from $27, Piper Jaffray doubled its...

FinanzNachrichten.de:  Jan 5 2010 3:28PM
Matching: xifaxan
Find similar documents
HTML
100%
Salix Pharmaceuticals up 6.5% on Piper Jaffray Share Pricing (SLX...
Company: Salix Pharmaceuticals, Ltd.

(SLXP) 01/05/2010-Shares of Salix Pharmaceuticals (NASDAQ:SLXP) are trading up 6.7% to $27.74 in afternoon activity on Tuesday and earlier surged $28.36, the highest intraday price since November 2000.

Piper Jaffray,...

Zibb:  Jan 5 2010 8:30PM
Matching: xifaxan
Find similar documents
HTML
100%
STOCKS NEWS US-Salix Pharma gains after brokers up targets
Stocks on the move Real-time Equity news U.S.

stock market report 1132 EST 5Jan2010-Salix Pharma gains after brokers up targets Shares of Salix Pharmaceuticals Inc rose on Tuesday after a pair of brokers raised their price targets on the stock, citing...

FinanzNachrichten.de:  Jan 5 2010 5:05PM
Matching: xifaxan
Find similar documents
HTML
100%
Salix Pharmaceuticals to Present at Piper Jaffray Conference
- Salix Pharmaceuticals, Ltd.

(NASDAQ:SLXP) today announced that the Company will present at the Piper Jaffray 21st Annual Health Care Conference in New York, NY on Tuesday, December 1 at 10:00 a.m.

Interested parties can access a live audio web cast of the...

Pharma Live:  Nov 24 2009 1:39PM
Matching: xifaxan
Find similar documents
HTML
100%
Salix Pharmaceuticals to Present at Piper Jaffray Conference
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd.

(NASDAQ:SLXP - News) today announced that the Company will present at the Piper Jaffray 21st Annual Health Care Conference in New York, NY on Tuesday, December 1 at 10:00 a.m.

Interested parties...

Business Wire via Yahoo!:  Nov 24 2009 12:06PM
Matching: xifaxan
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.